Atorvastatin induced gynecomastia in a dyslipidemic patient.

Statins, widely used for lowering low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, have demonstrated significant cardiovascular benefits. However, recent case reports have associated statins with gynecomastia, a condition characterized by benign breast tissue enlargement in males. Gynecomastia can cause significant discomfort and emotional distress. We present the case of a 66-year-old male who developed gynecomastia after two months of atorvastatin therapy at 20 mg/day. The patient, with a history of recent coronary artery bypass graft surgery, experienced pain, sensitivity, and growth in both mammary glands. Clinical examination and imaging revealed an increase in fibroglandular tissue, with no cystic or solid lesions. Laboratory tests ruled out other potential causes, including liver disease, hormonal imbalances, and the use of other medications known to cause gynecomastia. After switching the patient’s medication from atorvastatin to rosuvastatin 10 mg/day, a follow-up showed a reduction in pain, sensitivity, and mammary gland enlargement. This case underscores the importance of considering drug-induced gynecomastia when evaluating male patients on statin therapy. While rare, statin-induced gynecomastia is reversible upon discontinuation or modification of the treatment. Clinicians should be aware of this potential side effect to prevent unnecessary investigations and alleviate patient distress.